Medicore Research Inc
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reich, Dennis
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Active, not recruiting
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Recruiting
3
1450
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
08/24
04/25

Download Options